Everett E. Vokes
Vokes, Everett E., 1954-
Vokes, Everett E.
Vokes, E. E. (Everett E.), 1954-
Vokes, E. E. (Everett E.)
VIAF ID: 51936353 (Personal)
Permalink: http://viaf.org/viaf/51936353
Preferred Forms
- 100 0 _ ‡a Everett E. Vokes
- 200 _ | ‡a Vokes ‡b Everett E. ‡f 1954-....
- 100 1 _ ‡a Vokes, E. E. ‡q (Everett E.)
- 100 1 0 ‡a Vokes, E. E. ‡q (Everett E.), ‡d 1954-
-
-
-
- 100 1 _ ‡a Vokes, Everett E. ‡d 1954-
- 100 1 _ ‡a Vokes, Everett E. ‡d 1954-
- 100 1 _ ‡a Vokes, Everett E., ‡d 1954-
4xx's: Alternate Name Forms (12)
Works
Title | Sources |
---|---|
Abstracts of the 2nd International Chicago Symposium on Malignancies of the Chest and Head & Neck October 4 - 6, 2001, Chicago, Illinois, USA | |
Auge und Alter, Untersuchung von Heterophorie, Stereopsis und Zyklofusion an [siebzig] Probanden aller Altersstufen | |
Cancer of the upper gastrointestinal tract | |
Head and neck cancer | |
Oncologic therapies | |
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer | |
Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer | |
Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours | |
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin | |
Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies | |
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. | |
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report | |
Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer | |
Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). | |
Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer | |
Phase II trial of aminocamptothecin | |
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors | |
Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. | |
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma | |
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study | |
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers | |
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. | |
Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers | |
Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. | |
Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE). | |
Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer. | |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck | |
PROCLAIM: A Phase III Study of Pemetrexed, Cisplatin, and Radiation Therapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiation Therapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Locally Advanced Stage I | |
Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. | |
Prolonging Life, but at What Price? | |
Protein kinase C beta in malignant pleural mesothelioma | |
Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database | |
Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. | |
Radiation Therapy Oncology Group. Research Plan 2002-2006. Medical Oncology Committee. | |
Radioresistant tumor cell lines derived from head and neck radiation failures | |
Radiotherapy: Accelerated radiotherapy for HNSCC in developing countries | |
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial | |
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. | |
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. |